

# Cystic Fibrosis Diagnosis and Management in Children: A Simple Literature Review

Raghad Abdulrahman Rasheed<sup>1</sup>, Futoon Hussein Alsugheir<sup>2</sup>, Shaden Hussein Alsugheir<sup>2</sup>, Rayan Abdullah Alzaaqi<sup>2</sup>, Faris Almathanna Hijji<sup>2</sup>, Ali Saad Alharbi<sup>3</sup>, Safiah Ali Hashem Al Edrisy<sup>4</sup>, Omar Ibrahim Almarshad<sup>5</sup>, Shatha Ibrahim Matabi<sup>6</sup>, Donia Hashem Medher<sup>7</sup>, Zainab Hussain Alrashed<sup>8</sup>

<sup>1</sup> Department of Pediatric, Madinah Maternity and children hospital, Madinah, Saudi Arabia. <sup>2</sup> Department of Medical Science, Faculty of Medicine, King Saud bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia. <sup>3</sup> Department of Medical Science, Faculty of Medicine, Qassim University, Qassim, Saudi Arabia. <sup>4</sup> Department of Medical Science, Faculty of Medicine, Hashemite University, Amman, Jordan. <sup>5</sup> Department of Medical Science, Faculty of Medicine, Batterjee Medical College, Jeddah, Saudi Arabia. <sup>6</sup> Department of Medical Science, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia. <sup>7</sup> Department of Pediatric, Alaziziyah Children Hospital, Jeddah, Saudi Arabia. <sup>8</sup> Department of Medical Science, Faculty of Medicine, Medical university of Warsaw, Warszawa, Poland.

## Abstract

**Background:** Cystic fibrosis is a chronic inheritable disease presenting in newborns with lifelong complications. It is a common disease worldwide and in developing countries, like Saudi Arabia, a need for proper management is essential for the survival of affected children. **Objective:** The aim of this review was to evaluate the diagnostic and management approach of cystic fibrosis in the pediatric age group. **Methods:** We searched PubMed for (("Cystic Fibrosis"[MeSH]) AND ("Evaluation"[MeSH] OR "Management"[MeSH] OR "Diagnosis"[MeSH])) **Conclusion:** Complications and their prevention should be dutifully explained to parents as it would build their confidence as caretakers. Emphasis on diet and adherence to management plan would support the patient's lifestyle. Combined treatment of Ivacaftor and lumacaftor helps reduce respiratory complications, hospitalizations, and antibiotic use in CF patients. Correct management of this illness is crucial to the child's survival and multifactorial, with many afflicted reaching adulthood. Fortunately, there has been an improvement in the management of CF due to CFTR modulators, but most of them are for children older than 12 or 6-12 years of age and have side effects and high costs. The new era of research in this disease focuses on new and better drugs.

**Keywords:** Cystic Fibrosis, Diagnosis, Management

## INTRODUCTION

One of the important autosomal recessive disorders is cystic fibrosis (CF), an inheritable mutation in the gene of cystic fibrosis transmembrane conductance regulator (CFTR) protein. The advances in medical research have greatly helped in the management of cystic fibrosis, a complex disease that once linked early death to young children. The current survival rate of cystic fibrosis with adequate management reaches the age of forty. This is not true for all countries, as states in developed countries are struggling with the development of health care. Cystic fibrosis is usually diagnosed early in life, on average at two months of age. This review summarizes trending and existing knowledge on cystic fibrosis, with a highlight on diagnosis and management.

## METHODOLOGY

PubMed database was used for articles selection, and the following keywords were used in the MeSH: (("Cystic Fibrosis"[MeSH]) AND ("Evaluation"[MeSH] OR "Management"[MeSH] OR "Diagnosis"[MeSH])). Regarding the inclusion criteria, the articles were selected

based on the relevance to the project, which should include one of the following topics; CF evaluation, and CF management and diagnosis. Exclusion criteria were all other articles that did not have one of these topics as their primary endpoint, or meta-analysis, systematic reviews, or repeated studies.

**Address for correspondence:** Raghad Abdulrahman Rasheed. Department of Pediatric, Madinah Maternity and children hospital, Madinah, Saudi Arabia.  
E-mail: dr.raghad12 @ gmail.com

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.

**How to cite this article:** Abdulrahman Rasheed, R., Hussein Alsugheir, F., Hussein Alsugheir, Sh., Abdullah Alzaaqi, R., Almathanna Hijji, F., Saad Alharbi, A. and et al. Cystic Fibrosis Diagnosis and Management in Children: A Simple Literature Review. Arch Pharma Pract 2019;10(3):33-6.

## DISCUSSION

CF disease is a systemic and dangerously progressive lung disease that continues to be a major cause of mortality and morbidity for most patients. Over a patient-dependent and highly variable time course ranging from months to decades after birth, patients eventually develop chronic infection of the respiratory tract with a characteristic array of bacterial flora that leads to respiratory insufficiency and inevitable failure<sup>[1]</sup>. The physical and chemical abnormalities of these airway secretions result in chronic infection with phenotypically unique bacteria, particularly *Pseudomonas* species, with many patients requiring lung transplants<sup>[2, 3]</sup>. Other genetic factors including polymorphisms of the tumor necrosis alpha (TNF- $\alpha$ ) gene, may increase susceptibility to *P. aeruginosa* infection and contribute to the clinical manifestations of CF. Primary abnormalities in fatty acid metabolism have increased tissue expression of arachidonic acid with its metabolites leading to the inflammation indicative of CF. Cystic fibrosis is common in many countries worldwide, including developed and developing countries. CFTR genetic mutations in Arabian populations is comparable to that of other races<sup>[4]</sup>. Studies have speculated the high consanguineous rate in Saudis with CF genetic mutations<sup>[5]</sup>. A retrospective study in Saudi Arabia, identified high hematocrit, low mean corpuscular volume, low mean corpuscular hemoglobin concentration, and low albumin as factors related to mortality in CF, and recommended iron supplementation even in the presence of a normal serum hemoglobin level.<sup>[6]</sup>

## Pathogenesis

CF patients have abnormal transport of sodium and chloride across secretory epithelia, which results in thickened and viscous secretions in the reproductive system, intestines, pancreas, biliary tract, and bronchi. Cystic fibrosis is caused by mutations in a single large gene on chromosome 7 that encodes the CFTR protein. Moreover, to develop the full clinical picture of the diseases, mutations in both copies of the CFTR gene are required, hence the autosomal recessive pattern of inheritance. The function of this gene is as a regulator for chloride channel, and thus the activity of chloride and sodium channels at the cell surface. There are multiple ways for the mutations to occur, and they are divided by five classes (from I to V - ranging from defective protein production and protein processing to the decreased amount of functional CFTR). Additionally, some patients have gene modifiers exacerbating the severity and/or clinical manifestations of the disease. The main ones are transforming growth factor-beta (TGF- $\beta$ ) and Mannose-binding lectin and approximately 20 percent of CF patients carry these variants<sup>[7]</sup>.

## Diagnosis

The diagnosis of CF is based upon compatible clinical findings with a biochemical or genetic confirmation. The sweat chloride test is the mainstay of laboratory confirmation, although tests for pancreatic enzyme secretion, stool fecal fat,

immunoreactive trypsinogen, nasal potential difference, or specific mutations may also be useful in some cases. Overall, diagnosis is based on criteria, which imply the presence of clinical signs consistent with CF in at least one organ system plus evidence CFTR dysfunction (any elevated sweat chloride  $\geq 60$  mmol/L on 2 occasions, or the presences of 2 disease-causing mutations in CFTR, one from each parental allele, or abnormal nasal potential difference). However, this criterion is not required for newborns identified through a screening program or for siblings of patients with CF who are diagnosed by shared genotype<sup>[8]</sup>. A recent review of CF screening showed that 29 mmol/L could be the upper limit of normal, with 30-59 mmol/L suspicious of CF and require further investigation and follow-up<sup>[9]</sup>.

## Management Approach

When a child is diagnosed with CF, support and information should be directed towards the parents and caretakers. It would be in their favor to establish confidence in the medical team and themselves at the beginning while having supplementary information on taking care of their child at home. Explaining the disease, how it progresses, management routine and emergencies, and common complications with their signs all can educate the caretakers and help them stand on their feet<sup>[10]</sup>. The main aim of treatment should be to control the symptoms of the disease and prevent any further complications. CF patients require greater care when it comes to protecting their bodies from infections. Avid control of airway inflammation is achieved by NSAIDs, inhaled steroids, and cromolyn<sup>[11]</sup>. Their family and caretakers need to be aware of infection control measures early on, and this can be in the form of antibiotics including tobramycin inhaled powder and others, as to prevent unnecessary discomfort and complications to their dependants<sup>[12, 13]</sup>. The lungs in CF are viscous and filled to the brim with mucus secretions, and it is, therefore, optimal to reduce this viscosity and dilate the airways with humidified oxygen and beta-agonists while adding hypertonic saline and dornase alfa to the therapeutic mixture<sup>[14, 15]</sup>. Additionally, physiotherapy and including positive expiratory pressure (PEP) device or a high-frequency chest wall oscillation device (a percussion vest) is helpful<sup>[16]</sup>.

### • Complication Management

Complications are common in cystic fibrosis and may present as the diagnostic feature. CF newborns may suffer from meconium ileus as they develop other complications such as upper airway disease, osteoporosis, and muscle pain. CF children are often underdeveloped and malnourished with vitamin deficiencies (fat-soluble i.e. vitamins A, D, E, and K). A study in Bahrain showed that most CF patients suffer from malnourishment and that gastroesophageal reflux and low weight were risk factors for this problem<sup>[24]</sup>. When they reach adulthood, they may suffer from chronic liver disease and diabetes. Fertility is nonexistent in males and only reduced in female patients. It is common for CF patients to develop renal stones and joint pain<sup>[10]</sup>. Low water content in secretions from the respiratory, pancreatic, and biliary epithelium causes respiratory secretions to be of viscous nature. Being difficult

to clear, they would cause chronic airway obstruction and reduce bactericidal ability, developing into progressive pulmonary colonization with pathogens and formation of bacterial biofilms. Chronic infection causes an inflammatory response and tissue destruction, causing bronchiectasis. Abnormal bile and pancreatic secretions cause maldigestion and malabsorption, progressive liver and pancreatic disease, rectal prolapse, and intestinal obstruction (distal intestinal obstruction syndrome or intussusception) as aforementioned.

Lifestyle is greatly altered by disease, but actively advocating proper exercise to the patients motivates them to better lives. The participation of cystic fibrosis-affected individuals in daily exercise would benefit them with improved breathing, ease of muscle function, and decreased bone loss from non-use [10]. Although recent research has not shown significant improvement in the quality of life or forced expiratory volume, this should not discourage patients from being active [17]. Moreover, CF-affected children have lower exercise capacity than healthy children [18]. One randomized control trial in Canada has recommended the use of positive expiratory pressure devices or high-frequency chest wall oscillation devices [16]. Gastrointestinal symptoms often complicate CF disease and should be addressed early on. Oral rehydration, combined with osmotic laxatives and or enemas are utilized in the treatment and cautionary prevention of associated intestinal obstructions. Although prophylactic therapy is commonly used, it is not evidence-based [19]. Pancreatic enzyme replacement therapy contains a cocktail of proteases, lipases, and amylases that are helpful in managing the pancreatic insufficiency [20].

#### • Recent Advances

The main mechanism that stands behind CF development is the structural and functional abnormalities of CFTR protein. As a result, recent studies are focusing on solving this point. Ivacaftor, which is a recent drug used in the management of CF improves respiratory function with unprecedented alleviation of breathing symptoms, lowered rate of exacerbations, and decreased sweat chloride [20]. It works by increasing the time of channel in open state. However, it works only on G551D mutation patients, which represent 2.3% of CF patients. Fortunately, lumacaftor has shown desirable results in class II mutation, which is the most common mutation in CF patients. Lumacaftor acts on the dysfunctional processing of proteins by increasing the transport of protein to the cell surface. However, no correction of the underlying functional impairment and no significant improvement in FEV1, CFQR scores, and respiratory exacerbation rates were observed [21]. Adjunct therapy with Ivacaftor has been studied in combination with lumacaftor (Orkambi) and showed promising results in homozygous class II mutation patients older than 12 years. There was a 30-39% decrease in pulmonary complications along with better FEV1, decreased exacerbations and hospitalizations, and increased BMI and CFQR scores compared to a placebo [22,23].

## CONCLUSION

The appropriate management of this illness is crucial to the child's survival and multifactorial, with many patients reaching the midst of adulthood. Combination treatments reducing complications and exacerbations associated with dietary and lifestyle modifications should result in improved healthcare for CF patients and the comfort of their caretakers. Fortunately, there is an improvement in the management of CF due to the CFTR modulators, but most of them are for older children either >12 or 6-12 years of age and they risk their own side effects along with the high cost. The new era of research in this disease focuses on new and better drugs. The social burden of disease on the caretakers and patients should be investigated in an effort to lighten the psychological and monetary load. Furthermore, novel gene engineering methods and molecular targeting are being explored as new therapeutic techniques that may yet to be unraveled.

## REFERENCES

1. Khan MA, Ali ZS, Swezey N, Grasemann H, Palaniyar N. Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation. *Genes*. 2019 Mar;10(3):183.
2. Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and *Pseudomonas aeruginosa* infection. *BMC pulmonary medicine*. 2016 Dec;16(1):174.
3. Nourmohammadi E, Nedaeinia R, Goli M, Hosseini Teshnizi S, Sarkarizi H, Sarkarizi K, Nedaeinia M, Faraji H. Novel application of Nanotechnology in drug and Gene delivery: emphasis on Liposomes. *International Journal of Pharmaceutical and Phytopharmacological Research*. 2018 Dec;8(6):81-91.
4. Kambouris M, Banjar H, Moggari I, Nazer H, Al-Hamed M, Meyer BF. Identification of novel mutations in Arabs with cystic fibrosis and their impact on the cystic fibrosis transmembrane regulator mutation detection rate in Arab populations. *European journal of pediatrics*. 2000 Apr 1;159(5):303-9.
5. Banjar H, Kambouris M, Meyer BF, Al-Mehaidib A, Mogarri I. Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia. *Annals of tropical paediatrics*. 1999 Mar 1;19(1):69-73.
6. Banjar H. Morbidity and mortality data of cystic fibrosis patients. *Saudi medical journal*. 2003 Jul 1;24(7):730-5.
7. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. *Science*. 1992 May 8;256(5058):774-9.
8. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, LeGrys VA, Massie J, Parad RB, Rock MJ. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. *The Journal of pediatrics*. 2008 Aug 1;153(2):S4-14.
9. Castellani C, Massie J. Emerging issues in cystic fibrosis newborn screening. *Current opinion in pulmonary medicine*. 2010 Nov 1;16(6):584-90.
10. Villanueva G, Marceniuk G, Murphy MS, Walshaw M, Cosulich R. Diagnosis and management of cystic fibrosis: summary of NICE guidance. *BMJ*. 2017 Oct 26;359:j4574.
11. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel Jr PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. *American journal of respiratory and critical care medicine*. 2007 Nov 15;176(10):957-69.
12. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis

- patients: the EAGER trial. *Journal of Cystic Fibrosis*. 2011 Jan 1;10(1):54-61.
13. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. *Chest*. 2002 Jan 1;121(1):55-63.
  14. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW, Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. *The Journal of pediatrics*. 2001 Dec 1;139(6):813-20.
  15. Salvatore D, D'Andria M. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. *Pediatric pulmonology*. 2002 Jul;34(1):11-5.
  16. McIlwaine MP, Alarie N, Davidson GF, Lands LC, Ratjen F, Milner R, Owen B, Agnew JL. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. *Thorax*. 2013 Aug 1;68(8):746-51.
  17. Nevitt SJ, Hebestreit H, Kriemler S, Radtke T. Physical exercise training for cystic fibrosis. *The Cochrane Database of Systematic Reviews*. 2017 Nov;2017(11).
  18. Abdelbasset WK, Soliman GS, Elshehawy AA, Alrawaili SM. Exercise capacity and muscle fatiguability alterations following a progressive maximal exercise of lower extremities in children with cystic fibrosis. *African health sciences*. 2018;18(4):1236-42.
  19. Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. *J Cyst Fibros Off J Eur Cyst Fibros Soc*. 2011 Jun;10 Suppl 2:S24-28.
  20. Stern RC, Eisenberg JD, Wagener JS, Ahrens R, Rock M, doPico G, et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. *Am J Gastroenterol*. 2000 Aug;95(8):1932-8.
  21. Clancy, J P, Steven M Rowe, Frank J Accurso, Moira L Aitken, Raouf S Amin, Melissa A Ashlock, Manfred Ballmann, et al. "Results of a Phase IIa Study of VX-809, an Investigational CFTR Corrector Compound, in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR mutation." *Thorax* 67, no. 1 (August 2011): 12–18.
  22. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med*. 2011 Nov 3;365(18):1663–72.
  23. Wainwright, Claire E., J. Stuart Elborn, Bonnie W. Ramsey, Gautham Marigowda, Xiaohong Huang, Marco Cipolli, Carla Colombo, et al. "Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR." *New England Journal of Medicine* 373, no. 3 (2015): 220–31.
  24. Isa, Hasan, Lina Al-Ali, and Afaf Mohamed. "Growth Assessment and Risk Factors of Malnutrition in Children with Cystic Fibrosis." *Saudi Medical Journal* 37, no. 3 (January 2016): 293–98.